Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Non-Current Assets (2016 - 2025)

Ascendis Pharma A's Non-Current Assets history spans 8 years, with the latest figure at $123.8 million for Q4 2023.

  • For Q4 2023, Non-Current Assets fell 9.4% year-over-year to $123.8 million; the TTM value through Dec 2023 reached $123.8 million, down 9.4%, while the annual FY2023 figure was $124.5 million, 11.83% down from the prior year.
  • Non-Current Assets for Q4 2023 was $123.8 million at Ascendis Pharma A, down from $136.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $319.2 million in Q4 2021 and bottomed at -$882.5 million in Q4 2020.
  • The 5-year median for Non-Current Assets is $123.8 million (2023), against an average of -$46.0 million.
  • The largest annual shift saw Non-Current Assets skyrocketed 143.98% in 2019 before it plummeted 1315.95% in 2020.
  • A 5-year view of Non-Current Assets shows it stood at $72.6 million in 2019, then tumbled by 1315.95% to -$882.5 million in 2020, then soared by 136.17% to $319.2 million in 2021, then crashed by 57.2% to $136.6 million in 2022, then dropped by 9.4% to $123.8 million in 2023.
  • Per Business Quant, the three most recent readings for ASND's Non-Current Assets are $123.8 million (Q4 2023), $136.6 million (Q4 2022), and $319.2 million (Q4 2021).